News Column

New Findings on Pulmonary Hypertension from Tongji Medical College Summarized (GAPDH is critical for superior efficacy of female bone marrow-derived...

July 30, 2014



New Findings on Pulmonary Hypertension from Tongji Medical College Summarized (GAPDH is critical for superior efficacy of female bone marrow-derived mesenchymal stem cells on pulmonary hypertension)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Lung Diseases and Conditions have been published. According to news reporting originating from Wuhan, People's Republic of China, by NewsRx correspondents, research stated, "Pulmonary arterial hypertension, a chronic lung disease, remains an unacceptable prognosis despite significant advances in conventional therapies. Stem cell therapy represents a novel and effective modality."

Our news editors obtained a quote from the research from Tongji Medical College, "This study was aimed to add new insight in gender differences of bone marrow-derived mesenchymal stem cells on therapy against pulmonary arterial hypertension and the underlying mechanism. By in vivo experiments, we showed for the first time female bone marrow-derived mesenchymal stem cells possessed a better therapeutic potential against monocrotaline-induced pulmonary arterial hypertension in C57BL/6J mice compared with male counterparts. In vitro experiments demonstrated superior function of female bone marrow-derived mesenchymal stem cells in cell proliferation, migration and [Ca(2+)]i kinetics. Moreover, we unexpectedly found that, compared with male ones, female bone marrow-derived mesenchymal stem cells had a higher expression level of glyceraldehyde-3-phosphate dehydrogenase and manipulations of its expression in female or male bone marrow-derived mesenchymal stem cells profoundly affected their cellular behaviours and therapeutic efficacies against pulmonary arterial hypertension."

According to the news editors, the research concluded: "Our results suggest that glyceraldehyde-3-phosphate dehydrogenase plays a critical role in determining the superior functions of female bone marrow-derived mesenchymal stem cells in cell therapy against pulmonary arterial hypertension by regulating [Ca(2+)]i signal-associated cellular behaviours."

For more information on this research see: GAPDH is critical for superior efficacy of female bone marrow-derived mesenchymal stem cells on pulmonary hypertension. Cardiovascular Research, 2013;100(1):19-27. (Oxford University Press - www.oup.com/; Cardiovascular Research - cardiovascres.oxfordjournals.org)

The news editors report that additional information may be obtained by contacting R. Tan, Dept. of Pathophysiology, Tongji Medical College, Huazhong Science and Technology University, Wuhan, People's Republic of China. Additional authors for this research include J. Li, X. Peng, L. Zhu, L. Cai, T. Wang, Y. Su, K. Irani and Q. Hu (see also Lung Diseases and Conditions).

Keywords for this news article include: Wuhan, People's Republic of China, Asia, Bone Marrow, Bone Research, Cardiovascular Diseases, Dehydrogenase, Enzymes and Coenzymes, Immune System, Lung Diseases and Conditions, Mesenchymal Stem Cells, Pulmonary Hypertension, Stem Cell Research, Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters